Key facts
- This page summarizes Gregory J. Flesher's Form 4 filing for Reneo Pharmaceuticals, Inc. (OKUR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Dec 2022, 17:09.
Gregory J. Flesher - 09 Dec 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- OKUR
- Reported as of
- 09 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2022, 17:09:05 UTC
- Prior SEC filing
- 14 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer P. Lam, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory J. Flesher filed Form 4 for Reneo Pharmaceuticals, Inc. (OKUR) on 13 Dec 2022.
Change
- Previous filing in this sequence was filed on 14 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPHM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 115,200
- Date
- 09 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPHM
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +300,000
- Change %
- Price
- $0.000000
- Shares after
- 300,000
- Date
- 09 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $1.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022.
Footnote F2
The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.